Loading
Cancer Cells and Metastasis / Nanoplatforms for Cancer Theranostics / Cancer Research and Treatments · Journal article
Bmemat · August 17, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review exploring the conceptual and mechanistic foundations for using engineered bacteria as programmable vectors for cancer therapy, with emphasis on synthetic biology, drug delivery, and immunomodulation. The article surveys preclinical strategies, bacterial-derived components, and references to ongoing clinical trials, but does not report primary clinical outcome data or comparative efficacy evidence.
Journal article. Cancer patients (referenced in context of ongoing clinical trials, but no specific population enrolled or analyzed in this review).
Bacteria exploit innate tropism for hypoxic tumor cores to serve as self-propelled, localized delivery platforms for cytotoxic agents, immunomodulators, and prodrug-converting enzymes. Engineered bacterial systems can respond to tumor-specific signals to minimize off-target effects and enhance therapeutic precision. Bacterial-derived components including outer membrane vesicles, spores, and metabolites can be functionally repurposed for cancer immunotherapy and targeted drug delivery.
No primary efficacy or safety data from clinical trials are reported; reference to 'ongoing clinical trials' is mentioned but results are not presented. Ongoing clinical trials demonstrate translational feasibility, though persistent challenges in safety, biocontainment, and manufacturing scalability remain unresolved.
Clinicians and researchers should recognize bacterial therapeutics as an emerging but largely preclinical and early-translational paradigm; this review frames the scientific rationale and challenges but does not provide evidence of clinical benefit sufficient to guide current practice.
This is a narrative review synthesizing preclinical concepts, mechanistic insights, and early translational work on engineered bacteria for cancer therapy; it raises questions and explores possibilities rather than reporting a primary clinical trial result or definitive evidence.
Clinicians and researchers should recognize bacterial therapeutics as an emerging but largely preclinical and early-translational paradigm; this review frames the scientific rationale and challenges but does not provide evidence of clinical benefit sufficient to guide current practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract The dynamic interplay between intratumoral bacteria and cancer progression has unveiled new avenues for precision oncology, positioning bacteria as versatile, programmable platforms for targeted therapy. This review systematically explores the dual roles of tumor‐associated microbiota‐both promoting and suppressing malignancy‐and highlights the transformative potential of engineered bacterial systems in cancer treatment. Capitalizing on their innate tropism for hypoxic tumor cores, bacteria serve as self‐propelled, living drug carriers capable of localized delivery of cytotoxic agents, immunomodulators, and prodrug‐converting enzymes. Advances in synthetic biology and nano‐biohybrid designs have further enabled the development of intelligent bacterial vectors that respond to tumor‐specific signals, thereby minimizing off‐target effects and enhancing therapeutic precision. We discuss innovative strategies in which bacteria are harnessed to remodel the immunosuppressive tumor microenvironment (TME), potentiate immune checkpoint therapies, and synergize with conventional modalities such as chemotherapy, radiotherapy, and photodynamic therapy. Emphasis is placed on bacterial‐derived components‐including outer membrane vesicles, spores, and metabolites‐that can be functionally repurposed for cancer immunotherapy and targeted drug delivery. Furthermore, we examine ongoing clinical trials that underscore the translational feasibility of bacterial therapeutics, while also addressing persistent challenges in safety, biocontainment, and manufacturing scalability. Looking forward, we envision a new paradigm in which engineered bacteria, integrated with real‐time imaging and personalized microbiome profiling, evolve from experimental tools into clinically deployable “living medicines.” By bridging synthetic biology, immunology, and materials science, bacteria‐based platforms offer a promising frontier for achieving potent, specific, and adaptable cancer therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.